An open-label Phase I study to assess the safety of NKR-2 treatment administration after a non-myeloablative preconditioning chemotherapy in relapse/refractory acute myeloid leukemia or myelodysplastic syndrome patients
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
